Cargando…

Adoptive immunotherapy for AML with CD123-engager T cells

Detalles Bibliográficos
Autores principales:	Bonifant, Challice, Torres, David, Joseph, Nicholos, Barth, Carolyn Arber, Velasquez, Mireya, Song, Xiao-Tong, Redell, Michele, Gottschalk, Stephen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645287/ http://dx.doi.org/10.1186/2051-1426-3-S2-P3

Ejemplares similares

Transgenic Expression of IL15 Retains CD123-Redirected T Cells in a Less Differentiated State Resulting in Improved Anti-AML Activity in Autologous AML PDX Models
por: Mu-Mosley, Hong, et al.
Publicado: (2022)

T cells expressing CD19-specific Engager Molecules for the Immunotherapy of CD19-positive Malignancies
por: Velasquez, Mireya Paulina, et al.
Publicado: (2016)

Improving the anti-acute myeloid leukemia activity of CD123-specific engager T cells by MyD88 and CD40 co-stimulation
por: Vaidya, Abishek, et al.
Publicado: (2022)

The Art and Science of Selecting a CD123-Specific Chimeric Antigen Receptor for Clinical Testing
por: Riberdy, Janice M., et al.
Publicado: (2020)

Costimulation to enhance the antitumor activity of CD19 eng T cells
por: Velasquez, Mireya, et al.
Publicado: (2015)

CD123 AML targeting by chimeric antigen receptors: A novel magic bullet for AML therapeutics?
por: Tettamanti, Sarah, et al.
Publicado: (2014)

CD123 Is Consistently Expressed on NPM1-Mutated AML Cells
por: Perriello, Vincenzo Maria, et al.
Publicado: (2021)

Survival outcomes of CD34(+)CD38(−)LSCs and their expression of CD123 in adult AML patients
por: Zahran, Asmaa M., et al.
Publicado: (2018)

SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells
por: Tahk, Siret, et al.
Publicado: (2021)

DOT1L Inhibition Sensitizes MLL-Rearranged AML to Chemotherapy
por: Liu, Wei, et al.
Publicado: (2014)

CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission
por: Xie, L H, et al.
Publicado: (2017)

Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities
por: Christodoulou, Ilias, et al.
Publicado: (2021)

Novel CD123 polyaptamer hydrogel edited by Cas9/sgRNA for AML-targeted therapy
por: Wu, Haibin, et al.
Publicado: (2021)

Bicistronic CAR-T cells targeting CD123 and CLL1 for AML to reduce the risk of antigen escape
por: Xie, Danni, et al.
Publicado: (2023)

FLT3‐ITD DNA and mRNA levels in AML do not correlate with CD7, CD33 and CD123 expression
por: Soare, Dan‐Sebastian, et al.
Publicado: (2020)

Epitope tagging of endogenous genes in diverse human cell lines
por: Kim, Jung-Sik, et al.
Publicado: (2008)

Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment
por: Bonnevaux, Hélène, et al.
Publicado: (2021)

Distinct signaling events promote resistance to mitoxantrone and etoposide in pediatric AML: a Children’s Oncology Group report
por: Long, Xin, et al.
Publicado: (2017)

Toxicity and management in CAR T-cell therapy
por: Bonifant, Challice L, et al.
Publicado: (2016)

Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML
por: Meyer, Jan-Erik, et al.
Publicado: (2021)

B7-h3-specific engager T cells for the immunotherapy of pediatric solid tumors
por: DeRenzo, Christopher, et al.
Publicado: (2015)

A Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy
por: Epperly, Rebecca, et al.
Publicado: (2020)

CAR-T cells dual-target CD123 and NKG2DLs to eradicate AML cells and selectively target immunosuppressive cells
por: Jin, Xin, et al.
Publicado: (2023)

Editorial: The Biological Landscape of Immunotherapy in AML
por: Isidori, Alessandro, et al.
Publicado: (2021)

CD86 Is Associated with Immune Infiltration and Immunotherapy Signatures in AML and Promotes Its Progression
por: Zhang, Qianqian, et al.
Publicado: (2023)

Adoptive tumour immunotherapy using human CD4+ T-cells.
por: Gold, J. E., et al.
Publicado: (1993)

Rapid Generation of TCR and CD8αβ Transgenic Virus Specific T Cells for Immunotherapy of Leukemia
por: Bajwa, Gagan, et al.
Publicado: (2022)

Epitope-engineered human hematopoietic stem cells are shielded from CD123-targeted immunotherapy
por: Marone, Romina, et al.
Publicado: (2023)

Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436
por: Uckun, Fatih M., et al.
Publicado: (2021)

Optimizing EphA2-CAR T Cells for the Adoptive Immunotherapy of Glioma
por: Yi, Zhongzhen, et al.
Publicado: (2018)

Donor-Derived CD123-Targeted CAR T Cell Serves as a RIC Regimen for Haploidentical Transplantation in a Patient With FUS-ERG+ AML
por: Yao, Sun, et al.
Publicado: (2019)

Increasing Role of Targeted Immunotherapies in the Treatment of AML
por: Greiner, Jochen, et al.
Publicado: (2022)

PB1884: ENGAGING INNATE IMMUNITY: A PHASE 1 DOSE ESCALATION STUDY TO ASSESS SAFETY AND TOLERABILITY OF AFM28 MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CD123-POSITIVE ACUTE MYELOID LEUKEMIA (AML)
por: Arnan, Montserrat, et al.
Publicado: (2023)

Diagnosis and Treatment of Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC)
por: Arber, Daniel A, et al.
Publicado: (2020)

A radiolabeled antibody targeting CD123(+) leukemia stem cells – initial radioimmunotherapy studies in NOD/SCID mice engrafted with primary human AML
por: Leyton, Jeffrey V., et al.
Publicado: (2015)

Work efficiency improvement of >90% after implementation of an annual inpatient blood products administration consent form
por: Lindsay, Holly, et al.
Publicado: (2018)

Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia
por: Caruso, Simona, et al.
Publicado: (2022)

Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123
por: Gauthier, Laurent, et al.
Publicado: (2023)

Harnessing T Cells to Target Pediatric Acute Myeloid Leukemia: CARs, BiTEs, and Beyond
por: Epperly, Rebecca, et al.
Publicado: (2020)

Adoptive immunotherapy of cancer with polyclonal, 10(8)-fold hyperexpanded, CD4(+ )and CD8(+ )T cells
por: Wang, Li-Xin, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_evlt7n83n270m7tcsii8a1td2e